February 07, 2025

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

The research of BioMed X team EDC – Extrachromosomal DNA in Cancer – has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies.

Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership with Merck. The data generated by this project has been acquired by Merck for further development, potentially leading to new therapeutic approaches in precision oncology.

Launched in August 2022, the collaboration aimed to unravel the mechanisms behind the formation, propagation, and impact of ecDNA in cancer cells using state-of-the-art single-cell screening and spatial technologies. The project was led by Dr. Alexandros Drainas, winner of the BioMed X Innovation Boot Camp, and mentored by Dr. Sebastian M. Waszak, Assistant Professor at EPFL, Lausanne, Switzerland. Industry guidance provided by Dr. Balca Mardin, Head of Target Discovery & Research at Merck.

The multidisciplinary BioMed X team made significant strides in understanding ecDNA biology by addressing fundamental questions, such as:

  • How can we detect and trace ecDNA?
  • How is ecDNA formed, and which genes promote or inhibit its formation?
  • How are ecDNA structures formed, propagated, and maintained?

The team’s research identified genes that may reduce ecDNA abundance in cancer cells. Additionally, Team EDC developed advanced spatial technologies to explore how ecDNA localization affects cancer cell adaptability. The project was completed earlier than expected thanks to the promising and unexpected results achieved by the team. These early findings may offer promising strategies for mitigating cancer heterogeneity and reducing the mechanisms driving therapeutic resistance, potentially improving the efficacy of existing treatments.

Dr. Thomas Rückle, Senior Vice President Research at the BioMed X Institute, emphasized the importance of this achievement: “Our collaboration with Merck has once again demonstrated the power of combining academic curiosity with industrial expertise. The knowledge gained from this project not only advances cancer research but also showcases the potential of ecDNA-targeted therapies. We look forward to continuing our successful partnership with Merck and our joint journey towards a deeper understanding of complex life-threatening diseases.”

Our latest News

discover more
DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

The aim of the project is to use special quantitative MRI to visualize early changes in the intervertebral disc and enable timely treatment. Ultrashort echo time (UTE) MRI opens up completely new approaches to preventive imaging that are difficult or impossible to achieve with conventional MRI methods. Full text in German below. DFG fördert Heidelberger […]

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Researchers from Heidelberg University’s Medical Faculty, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT) in Heidelberg have tested the use of targeted drugs in the initial treatment of newly diagnosed glioblastoma, an extremely aggressive brain tumor, in the multicenter study “NCT Neuro Master Match (N2M2)”. Of the five drugs […]

Global effort to sequence all life on Earth ramps up

Global effort to sequence all life on Earth ramps up

The Earth BioGenome Project is accelerating its efforts tenfold to sequence all life on Earth by 2035 Summary A global collaboration that includes experts at EMBL’s European Bioinformatics Institute (EMBL-EBI) has entered the second phase of its ambitious plan to sequence all 1.67 million known species on Earth by 2035.  The Earth BioGenome Project (EBP), a […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp